Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05824585 · ClinicalTrials.gov registry record · Phase 1
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Dizal Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 230
- Enrollment target
- 5
- Study locations
NCT05824585: Recruiting Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Dizal Pharmaceuticals.
NCT05824585 is a Phase 1 study of Lymphoma, Non-Hodgkin that is actively recruiting participants, run by Dizal Pharmaceuticals. The registered enrollment target is 230 participants, below the 385-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (40% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05824585, a Phase 1 study of Lymphoma, Non-Hodgkin, is actively recruiting participants, sponsored by Dizal Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 230 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.
Conditions Studied
Interventions
- DRUG DZD8586
Study Locations (5)
Victoria
- Research site - Ballarat
- Research site - Melbourne
New York
- Research site - New York
New South Wales
- Research site - Albury
Western Australia
- Research site - Perth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2027-10-30 |
| Phase | Phase 1 |
What NCT05824585 shows while recruiting
NCT05824585 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 385-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which DZD8586 is the first listed.
NCT05824585 lists 5 locations in 4 states (Victoria, New York, New South Wales).
Frequently Asked Questions
What is clinical trial NCT05824585 about?
NCT05824585 is a clinical study titled "DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and ...
What is the current status of trial NCT05824585?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2023-05-15. Estimated completion is 2027-10-30.
What conditions does trial NCT05824585 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT05824585?
The interventions under investigation include: DZD8586 (DRUG).
Who is sponsoring clinical trial NCT05824585?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05824585 being conducted?
This trial has 5 study locations across New York, New South Wales, Victoria, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05824585's enrollment target sits among peer trials
230 17th of 58 higher than 42 of 58 other Lymphoma, Non-Hodgkin trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI